33.92
전일 마감가:
$32.24
열려 있는:
$32.35
하루 거래량:
78,191
Relative Volume:
1.51
시가총액:
$133.60M
수익:
$36.84M
순이익/손실:
$-729.00K
주가수익비율:
-36.72
EPS:
-0.9237
순현금흐름:
$-10.02M
1주 성능:
+11.43%
1개월 성능:
-4.97%
6개월 성능:
-1.42%
1년 성능:
+115.73%
Vtv Therapeutics Inc Stock (VTVT) Company Profile
명칭
Vtv Therapeutics Inc
전화
336-841-0300
주소
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
VTVT
Vtv Therapeutics Inc
|
33.92 | 132.10M | 36.84M | -729.00K | -10.02M | -0.9237 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 개시 | Evercore ISI | Outperform |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2026-01-05 | 개시 | TD Cowen | Buy |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2019-05-30 | 개시 | H.C. Wainwright | Buy |
| 2018-04-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 개시 | Northland Capital | Outperform |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2015-09-04 | 개시 | Canaccord Genuity | Buy |
| 2015-08-24 | 개시 | Piper Jaffray | Overweight |
| 2015-08-24 | 개시 | Stifel | Buy |
모두보기
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
VTVT Q1 2026 Earnings: Surprise Profit Amid No RevenueEarnings Preview - newsline.com
Price-Driven Insight from (VTVT) for Rule-Based Strategy - Stock Traders Daily
vTv Therapeutics, Inc. Class A Financial Disclosures & SEC Filings - TradingView
VTVT Q1 2026 Earnings: Massive EPS Beat Driven by Non-Operational ItemsForward EPS Estimate - newsline.com
VTVT Technical Analysis | Trend, Signals & Chart Patterns | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
Stock options, 10-year term: inside vTv Therapeutics grant - Stock Titan
VTVT Stock Price, Quote & Chart | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
MSN Money - MSN
vTv Therapeutics Drops as Diabetes Study Date Approaches - Bez Kabli
vTv Therapeutics (VTVT) Edges Lower, Holding Above Key Support Amid ConsolidationRisk Parity Rebalance - thelegaladvocate.com
(VTVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VTVT Q1 2026 Earnings: Massive EPS Surprise Driven by a Non-Recurring GainEarnings Quality Score - The Legal Advocate
VTVT Q1 2026 Earnings: Massive EPS Beat Driven by One-Time Items, Stock DeclinesCEO Earnings Statement - The Legal Advocate
vTv Therapeutics Inc. (VTVT) Slips 3% as Resistance Holds; Traders Eye Support TestLow Beta Factor - newsline.com
vTv Therapeutics Q1 2026 Earnings: Massive EPS Surprise on One-Time Gains, Shares SlipProfit Margin Analysis - newsline.com
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Amid Revenue Shortfall and Stock DeclineEBITDA Estimate Trend - The Legal Advocate
vTv Therapeutics Inc. (VTVT) Q1 2026 Earnings: Massive EPS Surprise Despite No RevenueAnalyst Stock Picks - Newser
VTVT | vTv Therapeutics Inc. Class Insider Trading - Quiver Quantitative
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next - Yahoo Finance
(VTVT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
vTv Therapeutics (VTVT) Q1 2026 Earnings: EPS $1.65 Beats EstimatesRevenue Report - newser.com
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
TD Cowen Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $67 - Moomoo
Analyst Maintains Buy on vTv Therapeutics, Reiterates Unchanged $49 Price Target Amid Progress of Cadisegliatin Program - TipRanks
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 - Investing.com
vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq – Company Information and SEC Filing Details - Minichart
vTv Therapeutics (VTVT) Reports Strong Q1 Revenue and Trial Prog - GuruFocus
Is vTv Therapeutics (VTVT) 322.2% Overvalued After Q1 2026? EPS - GuruFocus
vTv Therapeutics Expands At-The-Market Share Program Capacity - TipRanks
Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount. - Bitget
vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin - Stock Titan
vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion - Stock Titan
vTv Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
vTv Therapeutics Inc. 1Q 2026: Revenue $36.8M, Net income $24.1M — 10-Q Summary - TradingView
Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash - Stock Titan
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
VTv Therapeutics: Q1 Earnings Snapshot - kare11.com
Oral type 1 diabetes drug advances: vTv expects cash through Phase 3 data - Stock Titan
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
vTv Therapeutics (VTVT) Projected to Post Earnings on Wednesday - MarketBeat
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Vtv Therapeutics Inc (VTVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):